JP2010520886A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010520886A5 JP2010520886A5 JP2009552927A JP2009552927A JP2010520886A5 JP 2010520886 A5 JP2010520886 A5 JP 2010520886A5 JP 2009552927 A JP2009552927 A JP 2009552927A JP 2009552927 A JP2009552927 A JP 2009552927A JP 2010520886 A5 JP2010520886 A5 JP 2010520886A5
- Authority
- JP
- Japan
- Prior art keywords
- treating
- compound according
- disease
- composition
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 69
- 125000000217 alkyl group Chemical group 0.000 claims description 40
- 239000003814 drug Substances 0.000 claims description 40
- 239000000203 mixture Substances 0.000 claims description 30
- 229940079593 drug Drugs 0.000 claims description 29
- 125000005843 halogen group Chemical group 0.000 claims description 28
- 239000003795 chemical substances by application Substances 0.000 claims description 26
- 201000010099 disease Diseases 0.000 claims description 23
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 23
- 125000000623 heterocyclic group Chemical group 0.000 claims description 20
- 238000000034 method Methods 0.000 claims description 20
- 229910052799 carbon Inorganic materials 0.000 claims description 12
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 11
- 229940124597 therapeutic agent Drugs 0.000 claims description 11
- 125000005842 heteroatom Chemical group 0.000 claims description 10
- 201000006417 multiple sclerosis Diseases 0.000 claims description 10
- 206010012601 diabetes mellitus Diseases 0.000 claims description 9
- 229910052757 nitrogen Inorganic materials 0.000 claims description 9
- 125000002723 alicyclic group Chemical group 0.000 claims description 8
- 229910052739 hydrogen Inorganic materials 0.000 claims description 8
- 210000002569 neuron Anatomy 0.000 claims description 8
- 208000020925 Bipolar disease Diseases 0.000 claims description 7
- 201000002364 leukopenia Diseases 0.000 claims description 7
- 231100001022 leukopenia Toxicity 0.000 claims description 7
- 229910052760 oxygen Inorganic materials 0.000 claims description 7
- 201000000980 schizophrenia Diseases 0.000 claims description 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 6
- 208000024827 Alzheimer disease Diseases 0.000 claims description 5
- 208000023105 Huntington disease Diseases 0.000 claims description 5
- 208000001132 Osteoporosis Diseases 0.000 claims description 5
- 208000018737 Parkinson disease Diseases 0.000 claims description 5
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 5
- 208000010693 Charcot-Marie-Tooth Disease Diseases 0.000 claims description 4
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims description 4
- 208000006011 Stroke Diseases 0.000 claims description 4
- 208000030886 Traumatic Brain injury Diseases 0.000 claims description 4
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 4
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 4
- 208000020431 spinal cord injury Diseases 0.000 claims description 4
- 229910052717 sulfur Inorganic materials 0.000 claims description 4
- 230000009529 traumatic brain injury Effects 0.000 claims description 4
- 125000001153 fluoro group Chemical group F* 0.000 claims description 3
- 238000000338 in vitro Methods 0.000 claims description 3
- 230000002401 inhibitory effect Effects 0.000 claims description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 2
- 102000002254 Glycogen Synthase Kinase 3 Human genes 0.000 claims description 2
- 108010014905 Glycogen Synthase Kinase 3 Proteins 0.000 claims description 2
- 108010025020 Nerve Growth Factor Proteins 0.000 claims description 2
- 102000007072 Nerve Growth Factors Human genes 0.000 claims description 2
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims description 2
- 230000033115 angiogenesis Effects 0.000 claims description 2
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 2
- 230000001028 anti-proliverative effect Effects 0.000 claims description 2
- 239000012472 biological sample Substances 0.000 claims description 2
- 150000001721 carbon Chemical group 0.000 claims description 2
- 230000000973 chemotherapeutic effect Effects 0.000 claims description 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 2
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 claims description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
- 239000002955 immunomodulating agent Substances 0.000 claims description 2
- 229940121354 immunomodulator Drugs 0.000 claims description 2
- 229960003444 immunosuppressant agent Drugs 0.000 claims description 2
- 239000003018 immunosuppressive agent Substances 0.000 claims description 2
- 208000033065 inborn errors of immunity Diseases 0.000 claims description 2
- 208000028867 ischemia Diseases 0.000 claims description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 2
- 125000002757 morpholinyl group Chemical group 0.000 claims description 2
- 230000004766 neurogenesis Effects 0.000 claims description 2
- 239000003900 neurotrophic factor Substances 0.000 claims description 2
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 2
- 238000000554 physical therapy Methods 0.000 claims description 2
- 125000004193 piperazinyl group Chemical group 0.000 claims description 2
- 125000003386 piperidinyl group Chemical group 0.000 claims description 2
- 208000028529 primary immunodeficiency disease Diseases 0.000 claims description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 2
- 238000011084 recovery Methods 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 239000003981 vehicle Substances 0.000 claims description 2
- 208000030507 AIDS Diseases 0.000 claims 3
- 206010012289 Dementia Diseases 0.000 claims 3
- 210000003050 axon Anatomy 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 210000001787 dendrite Anatomy 0.000 claims 1
- -1 fluoro compound Chemical class 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 4
- 108091000080 Phosphotransferase Proteins 0.000 description 3
- 102000020233 phosphotransferase Human genes 0.000 description 3
- 206010065040 AIDS dementia complex Diseases 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 230000003376 axonal effect Effects 0.000 description 1
- 238000010835 comparative analysis Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000031146 intracellular signal transduction Effects 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US90608607P | 2007-03-09 | 2007-03-09 | |
| US60/906,086 | 2007-03-09 | ||
| US95302007P | 2007-07-31 | 2007-07-31 | |
| US60/953,020 | 2007-07-31 | ||
| PCT/US2008/056423 WO2008112642A1 (en) | 2007-03-09 | 2008-03-10 | Aminopyrimidines useful as inhibitors of protein kinases |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010520886A JP2010520886A (ja) | 2010-06-17 |
| JP2010520886A5 true JP2010520886A5 (enExample) | 2012-04-05 |
| JP5520057B2 JP5520057B2 (ja) | 2014-06-11 |
Family
ID=39472801
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009552927A Expired - Fee Related JP5520057B2 (ja) | 2007-03-09 | 2008-03-10 | 蛋白キナーゼの阻害剤として有用なアミノピリミジン |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US8664219B2 (enExample) |
| EP (1) | EP2134707B1 (enExample) |
| JP (1) | JP5520057B2 (enExample) |
| CN (1) | CN101663295B (enExample) |
| AU (2) | AU2008226457B2 (enExample) |
| CA (1) | CA2679884A1 (enExample) |
| ES (1) | ES2435997T3 (enExample) |
| MX (1) | MX2009009590A (enExample) |
| NZ (1) | NZ579446A (enExample) |
| WO (1) | WO2008112642A1 (enExample) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2001296871A1 (en) | 2000-09-15 | 2002-03-26 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| US6660731B2 (en) | 2000-09-15 | 2003-12-09 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| WO2004072029A2 (en) | 2003-02-06 | 2004-08-26 | Vertex Pharmaceuticals Incorporated | Pyrazolopyridazines useful as inhibitors of protein kinases |
| CN101316597B (zh) | 2005-11-03 | 2013-04-17 | 顶点医药品公司 | 用作激酶抑制剂的氨基嘧啶 |
| EP2086965B1 (en) | 2006-11-02 | 2010-02-10 | Vertex Pharmaceuticals, Inc. | Aminopyridines and aminopyrimidines useful as inhibitors of protein kinases |
| AU2007333650A1 (en) | 2006-12-19 | 2008-06-26 | Vertex Pharmaceuticals Incorporated | Aminopyrimidines useful as inhibitors of protein kinases |
| CN101678022A (zh) | 2006-12-21 | 2010-03-24 | 弗特克斯药品有限公司 | 可用作蛋白激酶抑制剂的5-氰基-4-(吡咯并[2,3b]吡啶-3-基)嘧啶衍生物 |
| JP5393489B2 (ja) | 2007-03-09 | 2014-01-22 | バーテックス ファーマシューティカルズ インコーポレイテッド | 蛋白キナーゼの阻害剤として有用なアミノピリミジン |
| JP2010520887A (ja) | 2007-03-09 | 2010-06-17 | バーテックス ファーマシューティカルズ インコーポレイテッド | 蛋白キナーゼの阻害剤として有用なアミノピリジン |
| MX2009009590A (es) | 2007-03-09 | 2009-11-10 | Vertex Pharma | Aminopirimidinas utiles como inhibidores de proteinas cinasas. |
| CA2683785A1 (en) | 2007-04-13 | 2008-10-23 | Vertex Pharmaceuticals Incorporated | Aminopyrimidines useful as kinase inhibitors |
| JP5389785B2 (ja) | 2007-05-02 | 2014-01-15 | バーテックス ファーマシューティカルズ インコーポレイテッド | キナーゼ阻害剤として有用なチアゾールおよびピラゾール |
| CA2694381A1 (en) | 2007-05-02 | 2008-11-13 | Vertex Pharmaceuticals Incorporated | Aminopyrimidines useful as kinase inhibitors |
| CN101790532B (zh) | 2007-07-31 | 2013-11-20 | 沃泰克斯药物股份有限公司 | 5-氟-1H-吡唑并[3，4-b]吡啶-3-胺及其衍生物的制备方法 |
| EP2262498A2 (en) * | 2008-03-10 | 2010-12-22 | Vertex Pharmceuticals Incorporated | Pyrimidines and pyridines useful as inhibitors of protein kinases |
| CN101768110B (zh) * | 2009-01-07 | 2012-09-12 | 上海开拓者化学研究管理有限公司 | 一种2-氯-5-氟吡啶-3-甲酸的制备方法 |
| AU2010262905B2 (en) | 2009-06-17 | 2015-04-16 | Vertex Pharmaceuticals Incorporated | Inhibitors of influenza viruses replication |
| EP2305274A1 (en) * | 2009-09-21 | 2011-04-06 | Centre National de la Recherche Scientifique (CNRS) | Use of WNT stimulators for treating demyelinating diseases |
| WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| EP2582709B1 (de) | 2010-06-18 | 2018-01-24 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
| US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
| TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
| TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
| TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
| KR20140014110A (ko) | 2010-12-16 | 2014-02-05 | 버텍스 파마슈티칼스 인코포레이티드 | 인플루엔자 바이러스 복제의 억제제 |
| UA118010C2 (uk) | 2011-08-01 | 2018-11-12 | Вертекс Фармасьютікалз Інкорпорейтед | Інгібітори реплікації вірусів грипу |
| WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| EP2760862B1 (en) | 2011-09-27 | 2015-10-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| EP2841428B1 (en) | 2012-04-24 | 2018-08-22 | Vertex Pharmaceuticals Incorporated | Dna-pk inhibitors |
| WO2014159690A1 (en) | 2013-03-12 | 2014-10-02 | Vertex Pharmaceuticals Incorporated | Dna-pk inhibitors |
| PL3424920T3 (pl) | 2013-10-17 | 2020-11-16 | Vertex Pharmaceuticals Incorporated | Kokryształy (S)-N-metylo-8-(1-((2'-metylo-4’,6'-dideutero-[4,5'-bipirymidyn]-6-ylo)amino)propan-2-ylo)chinolino-4-karboksyamidu i ich deuterowane pochodne jako inhibitory DNA-PK |
| EP3068782B1 (en) | 2013-11-13 | 2018-05-23 | Vertex Pharmaceuticals Incorporated | Methods of preparing inhibitors of influenza viruses replication |
| ES2741444T3 (es) | 2013-11-13 | 2020-02-11 | Vertex Pharma | Inhibidores de la replicación de virus de la gripe |
| WO2016183116A1 (en) | 2015-05-13 | 2016-11-17 | Vertex Pharmaceuticals Incorporated | Methods of preparing inhibitors of influenza viruses replication |
| WO2016183120A1 (en) | 2015-05-13 | 2016-11-17 | Vertex Pharmaceuticals Incorporated | Inhibitors of influenza viruses replication |
| WO2018064092A1 (en) | 2016-09-27 | 2018-04-05 | Vertex Pharmaceuticals Incorporated | Method for treating cancer using a combination of dna-damaging agents and dna-pk inhibitors |
Family Cites Families (80)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3133081A (en) * | 1964-05-12 | J-aminoindazole derivatives | ||
| US3935183A (en) * | 1970-01-26 | 1976-01-27 | Imperial Chemical Industries Limited | Indazole-azo phenyl compounds |
| BE754242A (fr) * | 1970-07-15 | 1971-02-01 | Geigy Ag J R | Diamino-s-triazines et dinitro-s-triazines |
| US3998951A (en) * | 1974-03-13 | 1976-12-21 | Fmc Corporation | Substituted 2-arylquinazolines as fungicides |
| DE2458965C3 (de) | 1974-12-13 | 1979-10-11 | Bayer Ag, 5090 Leverkusen | 3-Amino-indazol-N-carbonsäure-Derivate, Verfahren zu ihrer Herstellung sowie sie enthaltende Arzneimittel |
| MA18829A1 (fr) | 1979-05-18 | 1980-12-31 | Ciba Geigy Ag | Derives de la pyrimidine,procedes pour leur preparation,compositions pharmaceutiques contenant ces composes et leur utilisation therapeutique |
| DOP1981004033A (es) * | 1980-12-23 | 1990-12-29 | Ciba Geigy Ag | Procedimiento para proteger plantas de cultivo de la accion fitotoxica de herbicidas. |
| SE8102193L (sv) * | 1981-04-06 | 1982-10-07 | Pharmacia Ab | Terapeutiskt aktiv organisk forening och dess anvendning |
| SE8102194L (sv) * | 1981-04-06 | 1982-10-07 | Pharmacia Ab | Terapeutiskt aktiv organisk forening och farmaceutisk beredning innehallande denna |
| JPS58124773A (ja) * | 1982-01-20 | 1983-07-25 | Mitsui Toatsu Chem Inc | ５−メチルチオピリミジン誘導体とその製造法と農園芸用殺菌剤 |
| DE3725638A1 (de) | 1987-08-03 | 1989-02-16 | Bayer Ag | Neue aryloxy (bzw. thio)aminopyrimidine |
| US5710158A (en) * | 1991-05-10 | 1998-01-20 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
| JPH10509708A (ja) * | 1994-11-10 | 1998-09-22 | コア セラピューティクス，インコーポレイティド | プロテイン・キナーゼのインヒビターとして有用な医薬ピラゾール組成物 |
| IL117659A (en) * | 1995-04-13 | 2000-12-06 | Dainippon Pharmaceutical Co | Substituted 2-phenyl pyrimidino amino acetamide derivative process for preparing the same and a pharmaceutical composition containing same |
| US6716575B2 (en) * | 1995-12-18 | 2004-04-06 | Sugen, Inc. | Diagnosis and treatment of AUR1 and/or AUR2 related disorders |
| GB9619284D0 (en) * | 1996-09-16 | 1996-10-30 | Celltech Therapeutics Ltd | Chemical compounds |
| US6267952B1 (en) * | 1998-01-09 | 2001-07-31 | Geltex Pharmaceuticals, Inc. | Lipase inhibiting polymers |
| JP2000026421A (ja) | 1998-01-29 | 2000-01-25 | Kumiai Chem Ind Co Ltd | ジアリ―ルスルフィド誘導体及び有害生物防除剤 |
| CA2321153A1 (en) * | 1998-02-17 | 1999-08-19 | Timothy D. Cushing | Anti-viral pyrimidine derivatives |
| WO2000011003A1 (en) * | 1998-08-21 | 2000-03-02 | Du Pont Pharmaceuticals Company | ISOXAZOLO[4,5-d]PYRIMIDINES AS CRF ANTAGONISTS |
| US6184226B1 (en) * | 1998-08-28 | 2001-02-06 | Scios Inc. | Quinazoline derivatives as inhibitors of P-38 α |
| GB9828511D0 (en) * | 1998-12-24 | 1999-02-17 | Zeneca Ltd | Chemical compounds |
| GB9914258D0 (en) * | 1999-06-18 | 1999-08-18 | Celltech Therapeutics Ltd | Chemical compounds |
| US20020065270A1 (en) * | 1999-12-28 | 2002-05-30 | Moriarty Kevin Joseph | N-heterocyclic inhibitors of TNF-alpha expression |
| CZ20013540A3 (cs) * | 2000-02-05 | 2002-03-13 | Vertex Pharmaceuticals Incorporated | Deriváty pyrazolu jako inhibitory ERK a farmaceutický prostředek, který je obsahuje |
| AU2001237041B9 (en) * | 2000-02-17 | 2005-07-28 | Amgen Inc. | Kinase inhibitors |
| GB0004887D0 (en) * | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
| IL153246A0 (en) * | 2000-06-28 | 2003-07-06 | Astrazeneca Ab | Substituted quinazoline derivatives and their use as inhibitors |
| US6610677B2 (en) * | 2000-09-15 | 2003-08-26 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| US6660731B2 (en) | 2000-09-15 | 2003-12-09 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| AU2001296871A1 (en) * | 2000-09-15 | 2002-03-26 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| DE60122176T2 (de) * | 2000-09-15 | 2007-07-05 | Vertex Pharmaceuticals Inc., Cambridge | Isoxazole und ihre verwendung als erk-inhibitoren |
| US6613776B2 (en) * | 2000-09-15 | 2003-09-02 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| US7473691B2 (en) * | 2000-09-15 | 2009-01-06 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| US6641579B1 (en) * | 2000-09-29 | 2003-11-04 | Spectrasonics Imaging, Inc. | Apparatus and method for ablating cardiac tissue |
| US6716851B2 (en) * | 2000-12-12 | 2004-04-06 | Cytovia, Inc. | Substituted 2-aryl-4-arylaminopyrimidines and analogs as activators or caspases and inducers of apoptosis and the use thereof |
| DE10061863A1 (de) * | 2000-12-12 | 2002-06-13 | Basf Ag | Verfahren zur Herstellung von Triethylendiamin (TEDA) |
| HUP0400639A3 (en) * | 2000-12-21 | 2010-03-29 | Vertex Pharma | Pyrazole compounds useful as protein kinase inhibitors and pharmaceutical compositions containing them |
| MY130778A (en) | 2001-02-09 | 2007-07-31 | Vertex Pharma | Heterocyclic inhibitiors of erk2 and uses thereof |
| CA2441733A1 (en) * | 2001-03-29 | 2002-10-10 | Vertex Pharmaceuticals Incorporated | Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases |
| JP2004535381A (ja) * | 2001-04-13 | 2004-11-25 | バーテックス ファーマシューティカルズ インコーポレイテッド | ｃ−ＪｕｎＮ末端キナーゼ（ＪＮＫ）および他のプロテインキナーゼのインヒビター |
| US20030096813A1 (en) * | 2001-04-20 | 2003-05-22 | Jingrong Cao | Compositions useful as inhibitors of GSK-3 |
| AU2002308748A1 (en) * | 2001-05-16 | 2002-11-25 | Vertex Pharmaceuticals Incorporated | Heterocyclic substituted pyrazoles as inhibitors of src and other protein kinases |
| EP1399440B1 (en) * | 2001-06-15 | 2009-06-03 | Vertex Pharmaceuticals Incorporated | 5-(2-aminopyrimidin-4-yl)benzisoxazoles as protein kinase inhibitors |
| DE60214198T2 (de) * | 2001-07-03 | 2007-08-09 | Vertex Pharmaceuticals Inc., Cambridge | Isoxazolyl-pyrimidines als inhibitoren von src- und lck-protein-kinasen |
| US6698980B2 (en) * | 2001-07-30 | 2004-03-02 | Stewart Mining Products Inc. | Rock stabilizing apparatus and method |
| US6569499B2 (en) * | 2001-10-02 | 2003-05-27 | Xerox Corporation | Apparatus and method for coating photoreceptor substrates |
| MXPA04005510A (es) * | 2001-12-07 | 2006-02-24 | Vertex Pharma | Compuestos basados en pirimidina utiles como inhibidores de gsk-3. |
| WO2003078426A1 (en) * | 2002-03-15 | 2003-09-25 | Vertex Pharmaceuticals, Inc. | Azolylaminoazine as inhibitors of protein kinases |
| ATE365733T1 (de) * | 2002-03-15 | 2007-07-15 | Vertex Pharma | Zusammensetzungen brauchbar als protein-kinase- inhibitoren |
| EP1485380B1 (en) | 2002-03-15 | 2010-05-19 | Vertex Pharmaceuticals Incorporated | Azolylaminoazines as inhibitors of protein kinases |
| EP1485100B1 (en) * | 2002-03-15 | 2010-05-05 | Vertex Pharmaceuticals Incorporated | Azinylaminoazoles as inhibitors of protein kinases |
| US7863282B2 (en) | 2003-03-14 | 2011-01-04 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of protein kinases |
| US20030207873A1 (en) * | 2002-04-10 | 2003-11-06 | Edmund Harrington | Inhibitors of Src and other protein kinases |
| WO2003091246A1 (en) * | 2002-04-26 | 2003-11-06 | Vertex Pharmaceuticals Incorporated | Pyrrole derivatives as inhibitors of erk2 and uses thereof |
| MY141867A (en) * | 2002-06-20 | 2010-07-16 | Vertex Pharma | Substituted pyrimidines useful as protein kinase inhibitors |
| CA2491895C (en) * | 2002-07-09 | 2011-01-18 | Vertex Pharmaceuticals Incorporated | Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases |
| PL374967A1 (en) | 2002-08-02 | 2005-11-14 | Vertex Pharmaceuticals Incorporated | Pyrazole compositions useful as inhibitors of gsk-3 |
| WO2004037814A1 (en) | 2002-10-25 | 2004-05-06 | Vertex Pharmaceuticals Incorporated | Indazolinone compositions useful as kinase inhibitors |
| GB0317842D0 (en) * | 2003-07-30 | 2003-09-03 | Cyclacel Ltd | Compound |
| CA2542522A1 (en) | 2003-10-17 | 2005-05-06 | Astrazeneca Ab | 4-(pyrazol-3-ylamino) pyrimidine derivatives for use in the treatment of cancer |
| CA2547080A1 (en) * | 2003-12-02 | 2005-07-28 | Vertex Pharmaceuticals, Inc. | Heterocyclic protein kinase inhibitors and uses thereof |
| EP1917259B1 (en) | 2005-08-18 | 2012-01-25 | Vertex Pharmaceuticals Incorporated | Pyrazine kinase inhibitors |
| WO2007023382A2 (en) * | 2005-08-25 | 2007-03-01 | Pfizer Inc. | Pyrimidine amino pyrazole compounds, potent kinase inhibitors |
| ES2535854T3 (es) | 2005-09-30 | 2015-05-18 | Miikana Therapeutics, Inc. | Compuestos de pirazol sustituidos |
| CN101316597B (zh) | 2005-11-03 | 2013-04-17 | 顶点医药品公司 | 用作激酶抑制剂的氨基嘧啶 |
| DE602006021776D1 (de) | 2005-11-16 | 2011-06-16 | Vertex Pharma | Als kinaseinhibitoren geeignete aminopyrimidine |
| EP2086965B1 (en) | 2006-11-02 | 2010-02-10 | Vertex Pharmaceuticals, Inc. | Aminopyridines and aminopyrimidines useful as inhibitors of protein kinases |
| AU2007333650A1 (en) | 2006-12-19 | 2008-06-26 | Vertex Pharmaceuticals Incorporated | Aminopyrimidines useful as inhibitors of protein kinases |
| MX2009009590A (es) | 2007-03-09 | 2009-11-10 | Vertex Pharma | Aminopirimidinas utiles como inhibidores de proteinas cinasas. |
| JP5393489B2 (ja) | 2007-03-09 | 2014-01-22 | バーテックス ファーマシューティカルズ インコーポレイテッド | 蛋白キナーゼの阻害剤として有用なアミノピリミジン |
| JP2010520887A (ja) | 2007-03-09 | 2010-06-17 | バーテックス ファーマシューティカルズ インコーポレイテッド | 蛋白キナーゼの阻害剤として有用なアミノピリジン |
| MX2009010037A (es) | 2007-03-20 | 2009-11-05 | Vertex Pharma | Aminopirimidinas utiles como inhibidores de cinasas. |
| JP2010524962A (ja) | 2007-04-17 | 2010-07-22 | バーテックス ファーマシューティカルズ インコーポレイテッド | オーロラキナーゼ阻害剤のための創薬法 |
| JP5389785B2 (ja) | 2007-05-02 | 2014-01-15 | バーテックス ファーマシューティカルズ インコーポレイテッド | キナーゼ阻害剤として有用なチアゾールおよびピラゾール |
| MX2009011811A (es) | 2007-05-02 | 2010-01-14 | Vertex Pharma | Aminopirimidinas utiles como inhibidores de cinasa. |
| CA2694381A1 (en) | 2007-05-02 | 2008-11-13 | Vertex Pharmaceuticals Incorporated | Aminopyrimidines useful as kinase inhibitors |
| CN101687852A (zh) | 2007-05-24 | 2010-03-31 | 沃泰克斯药物股份有限公司 | 可用作激酶抑制剂的噻唑类和吡唑类化合物 |
| CN101790532B (zh) * | 2007-07-31 | 2013-11-20 | 沃泰克斯药物股份有限公司 | 5-氟-1H-吡唑并[3，4-b]吡啶-3-胺及其衍生物的制备方法 |
| EP3330255B1 (en) | 2009-03-20 | 2020-12-09 | Vertex Pharmaceuticals Incorporated | Process for making modulators of cystic fibrosis transmembrane conductance regulator |
-
2008
- 2008-03-10 MX MX2009009590A patent/MX2009009590A/es active IP Right Grant
- 2008-03-10 NZ NZ579446A patent/NZ579446A/en not_active IP Right Cessation
- 2008-03-10 ES ES08731830T patent/ES2435997T3/es active Active
- 2008-03-10 CN CN200880012693.9A patent/CN101663295B/zh not_active Expired - Fee Related
- 2008-03-10 CA CA002679884A patent/CA2679884A1/en not_active Abandoned
- 2008-03-10 JP JP2009552927A patent/JP5520057B2/ja not_active Expired - Fee Related
- 2008-03-10 EP EP08731830.9A patent/EP2134707B1/en not_active Not-in-force
- 2008-03-10 WO PCT/US2008/056423 patent/WO2008112642A1/en not_active Ceased
- 2008-03-10 AU AU2008226457A patent/AU2008226457B2/en not_active Ceased
-
2010
- 2010-06-02 US US12/791,976 patent/US8664219B2/en not_active Expired - Fee Related
-
2014
- 2014-01-15 US US14/155,624 patent/US20140194444A1/en not_active Abandoned
- 2014-06-18 AU AU2014203289A patent/AU2014203289A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010520886A5 (enExample) | ||
| JP2010520887A5 (enExample) | ||
| JP2010520889A5 (enExample) | ||
| RU2009137390A (ru) | Аминопиримидины, пригодные в качестве ингибиторов протеинкиназ | |
| DK2683244T3 (en) | Heterocyclic modulators of lipid synthesis | |
| EP2799435B1 (en) | Poly (adp-ribose) polymerase inhibitor | |
| DE60006580T2 (de) | Benzazolderivate und ihre verwendung als jnk modulatoren | |
| JP2010513567A5 (enExample) | ||
| US9809591B2 (en) | Heterocyclic modulators of lipid synthesis | |
| JP2003521537A (ja) | Ｅｒｋのインヒビターとして有用なピラゾール組成物 | |
| JP2010509231A5 (enExample) | ||
| JP2008513496A5 (enExample) | ||
| UA114178C2 (uk) | Комбінація, що включає інгібітор cdk4/6 і інгібітор pi3k, для лікування раку | |
| ES2934227T3 (es) | Inhibidores de isoindolinona de la interacción mdm2-p53 con actividad anticancerígena | |
| JP2010513285A5 (enExample) | ||
| JP2010538001A5 (enExample) | ||
| JP5901634B2 (ja) | キナゾリン化合物及びその使用方法 | |
| RU2004138819A (ru) | Ингибиторы протеинкиназ jak и cdk2 | |
| TW201808903A (zh) | 整合應激途徑之調節劑 | |
| JP2010532380A5 (enExample) | ||
| HUE028555T2 (en) | Pyrazolinquinoline Derivatives as PDE9 Inhibitors | |
| EP3156397A1 (en) | Nitrogen-containing heterocyclic compound | |
| AU2015241247B2 (en) | Prodrugs of HIV reverse transcriptase inhibitors | |
| EP3119795A1 (en) | Gemcitabine analogs | |
| NO20034031L (no) | Substituerte pyrazol- og tiazolpyrimidiner |